SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding CommitmentRANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors.
SK pharmteco Announces Successful FDA Inspection of Small Molecule Manufacturing Facility in La Porte, TexasRANCHO CORDOVA, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas.
SK pharmteco Announces CGMP Qualification of its Commercial-Scale Viral Vector Manufacturing Facility in FranceRANCHO CORDOVA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the successful CGMP qualification of its manufacturing facility in Corbeil-Essonnes, France. This state-of-the-art plant is now fully operational and prepared to support late-stage and commercial viral vector programs at scale.
